Table 2.
Liver-related characteristics, by HIV status
| Characteristics | HIV-positive (n=154) |
HIV-negative (n=227) |
Total (n=381) |
| Liver steatosis, n (%) | |||
| Yes | 5 (3) | 33 (15) | 38 (10) |
| No | 149 (97) | 194 (85) | 343 (90) |
| Steatosis staging, n (%) | |||
| S0 (CAP <248 dB/m) | 149 (96) | 194 (85) | 343 (90) |
| S1 (CAP 248–267 dB/m) | 4 (3) | 18 (8) | 22 (6) |
| S2 (CAP 268–279 dB/m) | 0 | 8 (4) | 8 (2) |
| S3 (CAP ≥280) | 1 (1) | 7 (3) | 8 (2) |
| Fibrosis/cirrhosis, n (%) | |||
| Yes | 14 (9) | 18 (8) | 32 (8) |
| No | 140 (91) | 209 (92) | 349 (92) |
| Fibrosis staging, n (%) | |||
| Normal | 140 (91) | 209 (92) | 349 (92) |
| Fibrosis (LSM ≥7 kPa) | 11 (7) | 13 (6) | 24 (6) |
| Cirrhosis (LSM≥11 kPa) | 3 (2) | 5 (2) | 8 (2) |
| ALT, median (IQR) | 24 (17–36) | 19 (15–29) | 21 (16–31) |
| ALT, n (%) | |||
| Normal | 79 (51) | 143 (63) | 222 (58) |
| Elevated (>20 U/mL for women; >30 U/mL for men) | 75 (49) | 84 (37) | 159 (42) |
| AST, median (IQR) | 36 (26–49) | 25 (20–32) | 28 (22–39) |
| AST, n (%) | |||
| Normal | 86 (56) | 190 (84) | 276 (72) |
| Elevated (>38 U/L) | 66 (43) | 33 (15) | 99 (26) |
| Missing | 2 (1) | 4 (1) | 6 (2) |
| ALP, median | 79 (65–105) | 70 (57–85) | 73 (59–89) |
| ALP, n (%) | |||
| Normal | 140 (91) | 217 (96) | 357 (94) |
| Elevated (138 U/L) | 10 (6) | 6 (3) | 16 (4) |
| Missing | 4 (3) | 4 (1) | 8 (2) |
ALP, alkaline phosphatase; ALT, alanine aminotransaminase; AST, aspartate aminotransferase; CAP, controlled-attenuation parameter; LSM, liver stiffness measure.